<DOC>
	<DOCNO>NCT00636558</DOCNO>
	<brief_summary>Coxsackie A21 ( CVA21 ) virus administer IV infusion patient Stage 4 melanoma , prostate breast cancer . This dose escalation , safety study .</brief_summary>
	<brief_title>Coxsackie Virus A21 Administered Intravenously ( IV ) Solid Tumour Cancers</brief_title>
	<detailed_description>This phase I , multiple dose , dose escalation , open label , cohort study three intravenous dos Coxsackie virus A21 patient stage IV solid tumour . Prospective patient attend study centre initial screening within 28 day prior commencement treatment . They nature study procedure risk fully explain . Patients must sign informed consent form give permission tumour test initial screening commence . Patients whose tumours test positive ICAM-1 without DAF attend study centre screen visit within 14 day prior commencement treatment . They sign full study inform consent form screening procedure carry . Patients satisfy inclusion none exclusion criterion commence treatment stage , consist one dose CVA21 administer intravenous infusion per dosage escalation chart . The first 4 cohort treat in-patients . The follow period consist 12 week , time patient attend trial centre to13 follow visit collect safety efficacy data .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Coxsackievirus Infections</mesh_term>
	<criteria>1 . Patients willing able provide write informed consent participate study . 2 . Male female age 18 year old . 3 . Stage IV solid tumour disease primary tumour one follow type breast , prostate melanoma . 4 . ICAM1 without DAFexpressing tumour . Patients without archival material testing must agree new tumour biopsy . 5 . Absence circulate antibody CVA21 ( titre &lt; 1:16 ) . 6 . Patients must fail refused standard treatment ( ) . 7 . Adequate haematological , hepatic renal function , define : ANC &gt; 1.5 x 10^9/L , platelet &gt; 100 x 10^9/L Bilirubin &lt; 20Âµmol/L , AST &lt; 2.5 time upper limit normal Calculated creatinine clearance &gt; 30 mL/minute 8 . Adequate immunologic function , define : Serum IgG &gt; 5g/L T cell subset within normal limit 9 . Fertile male female must agree use adequate form contraception . Hormonal contraceptive supplement additional barrier method . Negative pregnancy test require female patient childbearing potential . 1 . Presence history Central Nervous System ( CNS ) malignancy . 2 . Patients must receive chemotherapy within 4 week prior date consent . 3 . Performance status &gt; 1 Eastern Cooperative Oncology Group ( ECOG ) scale . 4 . Life expectancy &lt; 6 month . 5 . Pregnancy breastfeed . 6 . Primary secondary immunodeficiency , include immunosuppressive disease , immunosuppressive dos corticosteroid ( e.g . prednisolone &gt; 7.5mg per day ) immunosuppressive medication include cyclosporine , azathioprine , interferon , within past 4 week . 7 . Positive serology HIV , hepatitis B hepatitis C. 8 . Splenectomy . 9 . Presence uncontrolled infection . 10 . Presence unstable neurological disease . 11 . Any uncontrolled medical condition opinion Investigator likely place patient unacceptable risk study reduce ability complete study 12 . Participation another study require administration investigational drug biological agent within last 4 week 13 . Known allergy treatment medication excipients 14 . Any medical psychological condition would preclude participation study compromise ability give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>coxsackie virus</keyword>
	<keyword>melanoma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
</DOC>